Plus TherapeuticsPSTV
PSTV
About: Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Employees: 21
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0.11% more ownership
Funds ownership: 11.38% [Q3] → 11.49% (+0.11%) [Q4]
0% more funds holding
Funds holding: 10 [Q3] → 10 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
20% less capital invested
Capital invested by funds: $981K [Q3] → $780K (-$201K) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5.50
735%
upside
Avg. target
$7.25
1,001%
upside
High target
$9
1,267%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target | 1,267%upside $9 | Buy Maintained | 28 Mar 2025 |
HC Wainwright & Co. Sean Lee 48% 1-year accuracy 14 / 29 met price target | 735%upside $5.50 | Buy Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 7 articles about PSTV published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ
Positive
Zacks Investment Research
2 weeks ago
Plus (PSTV) Upgraded to Buy: Here's What You Should Know
Plus (PSTV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Seeking Alpha
3 weeks ago
Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.
Negative
Zacks Investment Research
3 weeks ago
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.70 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and full year ended December 31, 2024, and provides an overview of recent and upcoming business highlights. “Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in our two most advanced CNS cancer programs,” said Marc H.
Positive
Zacks Investment Research
4 weeks ago
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.
Neutral
GlobeNewsWire
4 weeks ago
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company's new proprietary name, REYOBIQ™, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ™ must be submitted once the marketing application (NDA) is submitted.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m.
Neutral
Accesswire
1 month ago
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. "This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies," said Marc H.
Neutral
GlobeNewsWire
1 month ago
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq's minimum stockholders' equity requirement. The Company's common stock will continue to be listed and traded on The Nasdaq Capital Market.
Charts implemented using Lightweight Charts™